Table 1.
Comparison of Group A, Group B and Group C
| Group A (n = 83) | Group B (n = 131) | Group C (n = 36) | P value | |
| Age (yr) | 56 (38-65) | 55 (3-72) | 51.5 (11-66) | 0.037 |
| Male/Female | 67/16 | 113/18 | 29/7 | 0.492 |
| Diagnosis: | ||||
| Cirrhosis | ||||
| Cryptogenic | 2 | 2 | 1 | |
| Hepatitis B | 67 | 89 | 25 | |
| Hepatitis C | 4 | 22 | 3 | |
| Alcoholic | 0 | 1 | 1 | |
| Hepatitis B + C | 1 | 2 | 0 | |
| Alcoholic + hepatitis C | 1 | 0 | 1 | |
| Alcoholic + hepatitis B | 0 | 1 | 0 | |
| Autoimmune | 1 | 0 | 0 | |
| Wilson's disease | 0 | 0 | 0 | |
| Preoperative MELD score | 13 (6-35) | 12 (6-35) | 12 (8-43) | 0.745 |
| Waiting time (d) | 94 (1-2735) | 31 ( 1-1874) | 35 (1-1473) | 0.001 |
| Blood transfusion (units) | 4.2 (0-32) | 2 (0-56) | 4 (0-31) | 0.128 |
| Fresh frozen plasma transfusion (units) | 8 (0-24) | 6 (0-30) | 6 (0-22) | 0.609 |
| Platelet transfusion (units) | 8 (0-26) | 6 (0-32) | 8 (0-22) | 0.978 |
| Operation time (min) | 650 (370-1105) | 678 (333-1110) | 707 (300-1273) | 0.598 |
| Cold ischemic time (min) | 182 (62-652) | 125 (60-633) | 133 (70-500) | 0.206 |
| Warm ischemic time (min) | 49.5 (25-102) | 52 (26-108) | 55.5 (30-93) | 0.209 |
| Hospital stay (d) | 1.7 (8-132) | 15 (0-83) | 15 (7-47) | 0.251 |
| Intensive care unit stay (d) | 3 (1-42) | 3 (0-30) | 3 (2-16) | 0.283 |
| Follow-up (mo) | 82.4 (0.59-204.9) | 89.1 (0-210.82) | 68.2 (5.95-204.24) | 0.242 |
| Hospital mortality | 2 (2.4%) | 2 (1.5%) | 0 | 0.626 |
| LDLT:DDLT | 45:38 | 93:38 | 28:8 | 0.012 |
| Explant Milan Within:Beyond | 56:23 | 84:46 | 15:21 | 0.010 |
| Explant UCSF Within:Beyond | 63:16 | 98:32 | 23:13 | 0.188 |
| No. of tumor in explant | 1 (1-multiple) | 2 (1-multiple) | 1 (1-20) | 0.272 |
| Largest size of tumor in explant (cm) | 2.5 (0.90-7.00) | 3.0 (0.25-9.00) | 4.0 (1.5-19.5) | 0.003 |
| Differentiation: | 0.017 | |||
| Well | 26 | 41 | 3 | |
| Moderate | 41 | 66 | 25 | |
| Poor | 2 | 8 | 6 | |
| Undifferentiated | 0 | 2 | 0 | |
| Unknown | 10 | 13 | 2 | |
| Vascular permeation: | 0.003 | |||
| No | 60 | 85 | 14 | |
| Yes | 18 | 40 | 21 | |
| Unknown | 1 | 5 | 1 | |
| Graft loss | 18 (21.7%) | 28 (21.4%) | 15 (41.7%) | 0.033 |
| Patient status Alive:Dead | 65:18 | 104:27 | 21:15 | 0.027 |
| Graft survival, yr | 0.038 | |||
| 1 | 96.40% | 93.10% | 97.20% | |
| 3 | 89.20% | 84.70% | 80.60% | |
| 5 | 85.50% | 81.60% | 66.00% | |
| Patient survival, yr | 0.029 | |||
| 1 | 96.40% | 94.70% | 97.20% | |
| 3 | 89.20% | 85.50% | 80.60% | |
| 5 | 85.50% | 82.40% | 66.00% | |
| Disease-free survival, yr | 0.007 | |||
| 1 | 92.80% | 89.30% | 80.60% | |
| 3 | 88.00% | 81.70% | 72.20% | |
| 5 | 84.30% | 80.10% | 61.10% | |
| Postoperative early complication by Clavien grading: | 0.702 | |||
| No | 40 | 68 | 20 | |
| I | 19 | 24 | 9 | |
| II | 5 | 13 | 2 | |
| IIIA | 11 | 11 | 3 | |
| IIIB | 6 | 6 | 2 | |
| IVA | 1 | 7 | 0 | |
| IVB | 0 | 0 | 0 | |
| V | 1 | 2 | 0 |
Group A-AFP < 10 ng/mL; Group B-AFP ≥ 10 to < 400 ng/mL; Group C, AFP ≥ 400 ng/mL. MELD: Model for end-stage liver disease; DDLT: Deceased-donor liver transplant; LDLT: Living-donor liver transplant.